In order to address the opportunities in oncology, peptides and iron compounds, Glenmark Life Science plans to build an R&D pipeline in the coming years
PRO Only Highlights
– Quarterly performance largely backed by improved realisations
– Medium-term triggers China plus and protectionist measures for tyre industry
– Valuations not inexpensive; but improved medium-term outlook
The IPO of Glenmark Life Sciences Limited (GLS) is catching investor attention because of the company’s strong chronic therapy portfolio that garners good margins (over 30 per cent EBITDA margin). What adds to the enthusiasm is the mega capex plan, which will help it gain traction in oncology APIs (active pharmaceutical ingredients) and enhance CDMO (contract development and manufacturing organisation) opportunity. Company brief Incorporated in 2011, GLS — the subsidiary of Glenmark Pharmaceuticals — is a key manufacturer of APIs in…
